Peter J Weiden

Summary

Affiliation: State University of New York
Country: USA

Publications

  1. ncbi Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone
    Peter J Weiden
    Department of Psychiatry, Box 1203, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    J Clin Psychopharmacol 23:595-600. 2003
  2. ncbi EPS profiles: the atypical antipsychotics are not all the same
    Peter J Weiden
    Dept of Psychiatry, SUNY Downstate Medical Center in Brooklyn, NY 11203, USA
    J Psychiatr Pract 13:13-24. 2007
  3. ncbi Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study
    Diana O Perkins
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
    J Clin Psychiatry 69:106-13. 2008
  4. doi A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, CA 92093 9116 A, USA
    J Clin Psychopharmacol 30:425-30. 2010
  5. doi Iloperidone for the treatment of schizophrenia: an updated clinical review
    Peter J Weiden
    Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612 7327, USA
    Clin Schizophr Relat Psychoses 6:34-44. 2012
  6. ncbi Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, 260 Stetson St, Suite 3224, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 70:4-46. 2009
  7. ncbi Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
    Peter J Weiden
    Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Neuropsychopharmacology 33:985-94. 2008
  8. doi A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome
    Peter J Weiden
    Center for Cognitive Medicine, Department of Psychiatry, University of Illinois, Chicago, IL 60612, USA
    J Clin Psychiatry 70:1397-406. 2009
  9. ncbi Understanding and treating "first-episode" schizophrenia
    Peter J Weiden
    Department of Psychiatry, University of Illinois Medical Center, Chicago, IL, USA
    Psychiatr Clin North Am 30:481-510. 2007
  10. ncbi Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia
    Peter J Weiden
    Department of Psychiatry, SUNY Downstate Medical Center State, Brooklyn, NY 11203, USA
    J Clin Psychiatry 64:580-8. 2003

Detail Information

Publications32

  1. ncbi Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone
    Peter J Weiden
    Department of Psychiatry, Box 1203, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    J Clin Psychopharmacol 23:595-600. 2003
    ....
  2. ncbi EPS profiles: the atypical antipsychotics are not all the same
    Peter J Weiden
    Dept of Psychiatry, SUNY Downstate Medical Center in Brooklyn, NY 11203, USA
    J Psychiatr Pract 13:13-24. 2007
    ..This review discusses differences among the SGAs in EPS liability, relationships between dosing and type of EPS, and situations in which differences in EPS liability among the SGAs are clinically relevant...
  3. ncbi Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study
    Diana O Perkins
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
    J Clin Psychiatry 69:106-13. 2008
    ..To evaluate predictors of treatment discontinuation against medical advice and poor medication adherence among first-episode patients treated with olanzapine, quetiapine, or risperidone...
  4. doi A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, CA 92093 9116 A, USA
    J Clin Psychopharmacol 30:425-30. 2010
    ....
  5. doi Iloperidone for the treatment of schizophrenia: an updated clinical review
    Peter J Weiden
    Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612 7327, USA
    Clin Schizophr Relat Psychoses 6:34-44. 2012
    ..This review is a comprehensive synthesis of the history and clinical trials data leading up to approval, and evaluates iloperidone within the clinical context of how it compares with other available antipsychotics...
  6. ncbi Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, 260 Stetson St, Suite 3224, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 70:4-46. 2009
    ..Summit faculty member opinion is compared with field survey results, and recommendations are made for future research...
  7. ncbi Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
    Peter J Weiden
    Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Neuropsychopharmacology 33:985-94. 2008
    ..These findings demonstrate that switching from risperidone or olanzapine to ziprasidone is associated with sustained, clinically significant improvements in weight and plasma lipids...
  8. doi A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome
    Peter J Weiden
    Center for Cognitive Medicine, Department of Psychiatry, University of Illinois, Chicago, IL 60612, USA
    J Clin Psychiatry 70:1397-406. 2009
    ..We report on acceptance and initial adherence outcomes with risperidone long-acting injection (RLAI) in first-episode schizophrenia patients...
  9. ncbi Understanding and treating "first-episode" schizophrenia
    Peter J Weiden
    Department of Psychiatry, University of Illinois Medical Center, Chicago, IL, USA
    Psychiatr Clin North Am 30:481-510. 2007
    ..Clinicians and treatment services should try to identify "first-episode" patients in time to be able to anticipate and address these issues...
  10. ncbi Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia
    Peter J Weiden
    Department of Psychiatry, SUNY Downstate Medical Center State, Brooklyn, NY 11203, USA
    J Clin Psychiatry 64:580-8. 2003
    ....
  11. ncbi The art and science of switching of antipsychotic medications, part 1
    Peter J Weiden
    Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center, Brooklyn, USA
    J Clin Psychiatry 67:e15. 2006
    ....
  12. ncbi Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C B 7160, University of North Carolina School of Medicine, Chapel Hill, 27599 7160, USA
    Schizophr Res 83:53-63. 2006
    ..Factors associated with treatment adherence in patients with chronic schizophrenia include beliefs about severity of illness and need for treatment, treatment with typical versus atypical antipsychotic and medication side effects...
  13. ncbi Understanding and addressing adherence issues in schizophrenia: from theory to practice
    Peter J Weiden
    Center for Cognitive Medicine, Department of Psychiatry, University of Illinois, Chicago 60612, USA
    J Clin Psychiatry 68:14-9. 2007
    ..5) Adherence behavior changes and fluctuates over time and should be considered as part of the illness in the context of the long-term trajectory of desired clinical outcomes such as recovery...
  14. ncbi Teaching medication compliance to psychiatric residents: placing an orphan topic into a training curriculum
    Peter J Weiden
    Schizophrenia Research Service, SUNY Downstate Medical Center, 450 Clarkson Ave, Brooklyn, New York 11203, USA
    Acad Psychiatry 29:203-10. 2005
    ..The objective of this article is to increase awareness about this vagueness among academic psychiatrists and to offer a suggested curriculum to facilitate implementation...
  15. ncbi Switching in the era of atypical antipsychotics. An updated review
    Peter J Weiden
    Department of Psychiatry, State University of New York, Downstate Medical Center Brooklyn, NY 11203, USA
    Postgrad Med . 2006
    ....
  16. ncbi Obesity as a risk factor for antipsychotic noncompliance
    Peter J Weiden
    SUNY Health Sciences Center at Brooklyn, Brooklyn, NY 11203 2098, USA
    Schizophr Res 66:51-7. 2004
    ..It is, therefore, increasingly important to understand the impact of obesity and perceived weight problems on compliance with these medications...
  17. ncbi Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial
    Peter J Weiden
    Department of Psychiatry, State University of New York Downstate Medical Center, Brooklyn 11203, USA
    J Clin Psychiatry 68:12-9. 2007
    ..Therefore, the clinical implications of the CATIE phase 1 findings may depend, in part, on the underlying assumptions of the ACD outcome measure...
  18. ncbi Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications
    Peter J Weiden
    Department of Psychiatry, State University of New York SUNY Downstate Medical Center, Brooklyn, NY, USA
    J Clin Psychiatry 68:14-23. 2007
    ..The authors explain how to evaluate the specific side effect in the context of the current medication and the overall management of the patient...
  19. ncbi Switching antipsychotics: an updated review with a focus on quetiapine
    Peter J Weiden
    Department of Psychiatry, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    J Psychopharmacol 20:104-18. 2006
    ..Finally, advice is provided on the assessments necessary when evaluating the success of a change in therapy, together with guidance on the optimal duration of treatment trials...
  20. ncbi Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia
    Peter J Weiden
    State University of New York SUNY Downstate Medical Center and King s County Hospital, Brooklyn, N Y, USA
    J Clin Psychiatry 68:34-9. 2007
    ....
  21. ncbi The art and science of switching antipsychotic medications, part 2
    Peter J Weiden
    Department of Psychiatry, Schizophrenia Research Program, State University of New York Downstate Medical Center and Kings County Hospital Center, Brooklyn, USA
    J Clin Psychiatry 68:e02. 2007
    ....
  22. ncbi Beyond psychopharmacology. Psychosocial strategies for getting the best results when switching antipsychotic medications
    Patricia L Scheifler
    Partnership for Recovery, Sylacauga, AL 35150, USA
    Postgrad Med . 2006
    ..It is also important to revisit the initial treatment goals to distinguish primary pharmacologic improvements from secondary psychologic reactions and challenges arising from those improvements...
  23. ncbi Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia
    Peter J Weiden
    State University of New York in Brooklyn, USA
    Psychiatr Serv 55:886-91. 2004
    ..The objective of this study was to evaluate the relationship between compliance with an antipsychotic medication regimen and risk of hospitalization in a cohort of California Medicaid patients with schizophrenia...
  24. ncbi Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder
    George M Simpson
    Department of Psychiatry and the Behavioral Sciences, LAC USC Medical Center, IRD RM 204, Psychiatric Outpatient Clinic, 2020 Zonal Ave, Los Angeles, CA 90033, USA
    Am J Psychiatry 161:1837-47. 2004
    ..The authors compared the efficacy and tolerability of ziprasidone and olanzapine in the treatment of acutely ill inpatients with schizophrenia or schizoaffective disorder...
  25. doi Antipsychotic-induced movement disorders - forgotten but not gone
    Peter J Weiden
    Acta Psychiatr Scand 117:401-2. 2008
  26. doi Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia
    Andrew J Cutler
    University of Florida, Gainesville, FL, USA
    J Clin Psychopharmacol 28:S20-8. 2008
    ..Overall, there was improvement in akathisia with iloperidone treatment. Iloperidone treatment was effective, safe, and well tolerated in patients with acute exacerbation of schizophrenia...
  27. doi Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials
    Peter J Weiden
    Center for Cognitive Medicine, Chicago, IL 60612, USA
    J Clin Psychopharmacol 28:S12-9. 2008
    ....
  28. ncbi Cognitive behavior therapy for schizophrenia
    Douglas Turkington
    Department of Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear NE4 4LP, UK
    Am J Psychiatry 163:365-73. 2006
    ..The objective of this article is to offer a broad perspective on the subject of cognitive behavior therapy for schizophrenia for the American reader...
  29. ncbi From clinical research to clinical practice: a 4-year review of ziprasidone
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
    CNS Spectr 10:1-20. 2005
    ..This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania...
  30. ncbi Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning
    David L Ginsberg
    Georgetown University School of Medicine, USA
    CNS Spectr 10:1-13; discussion 14-15. 2005
    ..Additionally, relative to older medications, atypicals have demonstrated benefit in improving some of the cognitive impairments...
  31. ncbi Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap
    Peter J Weiden
    University of Illinois at Chicago, USA
    J Clin Psychiatry 68:1-48. 2007
    ....
  32. ncbi Distress with medication side effects among persons with severe mental illness
    Nancy H Covell
    Division of Health Services Research, Mount Sinai School of Medicine, New York, NY, USA
    Adm Policy Ment Health 34:435-42. 2007
    ..The most distressing SEs reported were embarrassment from weight gain, weight gain, dry mouth, and sedation. The likelihood of distress by particular SEs varied by gender and race...